慢性乙型肝炎抗病毒治疗的药物评价  

Drug Evaluation of Antiviral Therapy on Chronic Hepatitis B

作　　者：王咏梅[1] 王霞[1] 岳秀娟[1] 

机构地区：[1]首都医科大学附属北京佑安医院,北京100069

出　　处：《药品评价》2010年第18期38-44,共7页Drug Evaluation

摘　　要：目的:了解慢性乙型肝炎抗病毒治疗现状,评价抗病毒治疗药物的临床应用和安全性,为临床合理用药提供参考。方法:通过收集国内外文献和慢性乙型肝炎治疗指南,从抗病毒治疗的药物选择和流程、药理作用、临床疗效、不良反应和临床耐药等方面进行综述。结果:口服核苷(酸)类似物和干扰素注射治疗是慢性乙型肝炎抗病毒治疗主要手段,并取得了良好临床疗效,但耐药变异是抗病毒治疗中目前面临的最大难题。结论:应规范合理使用核苷(酸)类似物,优化治疗方案,进行临床耐药管理,以降低耐药变异率。Objective： To comprehend the present situation of antivirus treatment of chronic hepatitis B, and appraise the clinical application and safety of antivirus treatment medicines, thus to provide reference for the clinical reasonable medication. Methods： Domestic and foreign literatures and the chronic hepatitis B treatment guidelines were collected, and review was made from the following aspects： the choice and flow of antivirus treatment medicines, the pharmacological action, the clinical curative effect, the adverse drug reactions and clinical drug resistence and so on. Results： Taking the nucleoside analogues （acids） orally and the interferon injection treatment are the principal means of antivirus treatment of chronic hepatitis B, which has obtained good clinical curative effect, but drug resistence variation is the biggest difficult problem in the antivirus treatment at present. Conclusion： Nucleoside analogues （acids） should be used reasonably, therapeutic schedule should be optimized, and clinical drug resistence should be carried out to reduce drug resistence variation rate.

关 键 词：慢性乙型肝炎 抗病毒治疗 药物评价 

分 类 号：R512.62[医药卫生—内科学]